HLA-haploidentical peripheral blood stem cell transplantation following reduced-intensity conditioning with very low-dose antithymocyte globulin for relapsed/refractory acute leukemia in pediatric patients: a single-institution retrospective analysis.
Adolescent
Age Factors
Antilymphocyte Serum
/ administration & dosage
Child
Child, Preschool
Female
Follow-Up Studies
Graft vs Host Disease
/ epidemiology
HLA Antigens
/ genetics
Haploidy
Humans
Infant
Leukemia, Myeloid, Acute
/ mortality
Male
Peripheral Blood Stem Cell Transplantation
/ adverse effects
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/ mortality
Recurrence
Retrospective Studies
Survival Rate
Transplantation Conditioning
/ methods
Treatment Outcome
Acute leukemia
Haploidentical peripheral blood stem cell transplantation
Low-dose ATG
Pediatric
Relapsed/refractory
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
02
07
2021
accepted:
01
12
2021
revised:
30
11
2021
pubmed:
15
1
2022
medline:
11
3
2022
entrez:
14
1
2022
Statut:
ppublish
Résumé
The prognosis of relapsed/refractory (R/R) pediatric acute leukemia is extremely poor. We retrospectively reviewed 20 consecutive pediatric patients with R/R acute leukemia who underwent a first HLA-haploidentical peripheral blood stem cell transplantation following reduced-intensity conditioning (haplo-RIC-PBSCT) with very low-dose antithymocyte globulin (ATG) between 2012 and 2019. Of these 20 patients, 7 patients had acute lymphoblastic leukemia, and 13 had acute myeloid leukemia. At the time of haplo-RIC-PBSCT, 15 patients had active disease. The median follow-up duration for survivors was 56 months (range 22-108 months). Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus, short-term methotrexate, methylprednisolone, and ATG 1.25 mg/kg on day-2. The 2-year cumulative incidence of transplant-related mortality and relapse were 5.0% [95% confidence interval (CI) 0.7-30.5%)] and 57.8% (95% CI 37.4-79.6%), respectively. Among the 20 patients, 16 (80.0%) developed grade III-IV acute GVHD, and 2 developed severe chronic GVHD. The 2-year event-free survival and overall survival rates were 40.0% (95% CI 19.3-60.0%) and 50.0% (95% CI 27.1-69.2%), respectively. Although the sample size is small, the survival outcomes of the present study are encouraging.
Identifiants
pubmed: 35028882
doi: 10.1007/s12185-021-03270-z
pii: 10.1007/s12185-021-03270-z
doi:
Substances chimiques
Antilymphocyte Serum
0
HLA Antigens
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
406-413Informations de copyright
© 2021. Japanese Society of Hematology.
Références
Hunger SP, Loh ML, Whitlock JA, Winick NJ, Carroll WL, Devidas M, et al. COG Acute Lymphoblastic Leukemia Committee. Children’s Oncology Group’s 2013 blueprint for research: acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013;60(6):957–63.
doi: 10.1002/pbc.24420
Schrappe M, Möricke A, Reiter A, Henze G, Welte K, Gadner H, et al. Key treatment questions in childhood acute lymphoblastic leukemia: results in 5 consecutive trials performed by the ALL-BFM study group from 1981 to 2000. Klin Padiatr. 2013;225(Suppl 1):S62-72.
pubmed: 23700060
Kato M, Manabe A. Treatment and biology of pediatric acute lymphoblastic leukemia. Pediatr Int. 2018;60(1):4–12.
doi: 10.1111/ped.13457
Gamis AS, Alonzo TA, Perentesis JP, Meshinchi S. COG Acute Myeloid Leukemia Committee. Children’s Oncology Group’s 2013 blueprint for research: acute myeloid leukemia. Pediatr Blood Cancer. 2013;60(6):964–71.
doi: 10.1002/pbc.24432
Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005;23:3447–54.
doi: 10.1200/JCO.2005.09.117
Handgretinger R. New approaches to graft engineering for haploidentical bone marrow transplantation. Semin Oncol. 2012;39:664–73.
doi: 10.1053/j.seminoncol.2012.09.007
Bethge WA, Faul C, Bornhäuser M, Stuhler G, Beelen DW, Lang P, et al. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update. Blood Cells Mol Dis. 2008;40(1):13–9.
doi: 10.1016/j.bcmd.2007.07.001
Lang P, Teltschik HM, Feuchtinger T, Müller I, Pfeiffer M, Schumm M, et al. Transplantation of CD3/CD19 depleted allografts from haploidentical family donors in paediatric leukaemia. Br J Haematol. 2014;165(5):688–98.
doi: 10.1111/bjh.12810
Schumm M, Lang P, Bethge W, Faul C, Feuchtinger T, Pfeiffer M, et al. Depletion of T-cell receptor alpha/beta and CD19 positive cells from apheresis products with the CliniMACS device. Cytotherapy. 2013;15:1253–8.
doi: 10.1016/j.jcyt.2013.05.014
Bertaina A, Merli P, Rutella S, Pagliara D, Bernardo ME, Masetti R, et al. HLA-haploidentical stem cell transplantation after removal of αβ+ T and B cells in children with nonmalignant disorders. Blood. 2014;124:822–6.
doi: 10.1182/blood-2014-03-563817
O’Donnell PV, Luznik L, Jones RJ, Vogelsang GB, Leffell MS, Phelps M, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8:377–86.
doi: 10.1053/bbmt.2002.v8.pm12171484
Ji SQ, Chen HR, Wang HX, Yan HM, Zhu L, Liu J, et al. G-CSF-primed haploidentical marrow transplantation without ex vivo T cell depletion: an excellent alternative for high-risk leukemia. Bone Marrow Transplant. 2002;30:861–6.
doi: 10.1038/sj.bmt.1703769
Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2006;107:3065–73.
doi: 10.1182/blood-2005-05-2146
Lee KH, Lee JH, Lee JH, Kim DY, Seol M, Lee YS, et al. Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. Blood. 2011;118:2609–17.
doi: 10.1182/blood-2011-02-339838
Kanda Y, Oshima K, Kako S, Fukuda T, Uchida N, Miyamura K, et al. In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation. Am J Hematol. 2013;88:294–300.
doi: 10.1002/ajh.23392
Ishihara T, Yasui M, Nakayama K, Kondo O, Koyama M, Sawada A, et al. Efficacy of continuous chemotherapy consisting of low dose etoposide and cytarabine in children. Jpn J Pediatr Hematol. 2008;22(5/6):347–53.
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304.
doi: 10.1097/00007890-197410000-00001
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945–56.
doi: 10.1016/j.bbmt.2005.09.004
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.
doi: 10.1038/bmt.2012.244
Ikegame K, Yoshida T, Yoshihara S, Daimon T, Shimizu H, Maeda Y, et al. Unmanipulated haploidentical reduced-intensity stem cell transplantation using fludarabine, busulfan, low-dose antithymocyte globulin, and steroids for patients in non-complete remission or at high risk of relapse: a prospective multicenter phase I/II study in Japan. Biol Blood Marrow Transplant. 2015;21:1495–505.
doi: 10.1016/j.bbmt.2015.04.012
Sano H, Mochizuki K, Kobayashi S, Ohara Y, Ito M, Waragai T, et al. T-cell-replete haploidentical stem cell transplantation using low-dose antithymocyte globulin in children with relapsed or refractory acute leukemia. Int J Hematol. 2018;108:76–84.
doi: 10.1007/s12185-018-2423-5
Sawada A, Shimizu M, Isaka K, Higuchi K, Mayumi A, Yoshimoto Y, et al. Feasibility of HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for advanced pediatric malignancies. Pediatr Hematol Oncol. 2014;31:754–64.
doi: 10.3109/08880018.2014.961214